非鴉片類鎮痛治療市場規模、佔有率和成長分析：按藥物類別、疼痛類型、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

2024 年全球非鴉片類止痛藥市場價值為 285.2 億美元，預計到 2025 年將成長至 305.5 億美元，到 2033 年將成長至 528.5 億美元，在預測期（2026-2033 年）內複合年成長率為 7.12%。

全球非鴉片類鎮痛治療市場正經歷顯著成長，其主要驅動力是有效控制慢性疼痛並減輕鴉片類藥物相關不良反應的迫切需求。該市場涵蓋多種藥物，例如非類固醇消炎劑（NSAIDs）、抗憂鬱症、抗驚厥藥和外用製劑，以及神經調控療法和射頻消融術等器械療法。該市場的重要性在於其能夠提供更安全、更有效的疼痛管理方案，從而降低發病率、減少成癮風險並降低醫療成本。製藥公司致力於研發特異性藥物和新型製劑，而醫療設備製造商則在拓展用於緩解慢性疼痛的神經調控技術。此外，保險公司正在建立報銷機制，以促進這些治療方法在臨床實踐中的應用，這凸顯了巨大的商業性和臨床機會。

全球非鴉片類鎮痛治療市場促進因素

隨著患者對非鴉片類鎮痛療法的偏好日益成長，醫療服務提供者和保險公司正尋求將這些治療方法納入治療方案。這些替代鎮痛方案的接受度不斷提高，將激勵製藥公司和醫療設備製造商加大研發投入，開發多元化的產品系列，並積極尋求監管部門核准其先進的非鴉片類解決方案。隨著替代鎮痛方法在臨床實踐中廣泛應用，由此帶來的市場擴張將贏得支付方的支持，並提升製造商的知名度。這一趨勢將加速商業化進程，並推動全球非鴉片類鎮痛治療市場的持續成長和投資。

全球非鴉片類鎮痛治療市場的限制因素

全球非鴉片類鎮痛市場面臨許多挑戰，法規結構的差異和複雜的核准流程給非鴉片類療法的研發者帶來了不確定性。這些因素可能導致產品在各市場上市延遲，並增加核准所需的時間和資源。這種複雜性可能會阻礙中小企業開發創新解決方案，並使全球商業化策略更加複雜。此外，臨床試驗要求和上市後監測預期方面的差異可能導致證據收集分散，以及醫療服務提供者和保險公司採用不一致。因此，投資可能受到限制，產品供應受阻，市場成長可能放緩。

全球非鴉片類鎮痛藥市場趨勢

全球非鴉片類鎮痛藥市場正顯著轉向精準化和個人化治療方法，其驅動力在於對患者分層和生物標記主導療法的重視。相關人員正增加對個人化製劑、標靶給藥機制和個人化照護路徑的投資，旨在提高疼痛管理介入措施的有效性並改善患者依從性。與專科診所、診斷服務提供者和製藥創新者合作對於開發差異化價值提案和在高階市場中佔有一席之地至關重要。此外，新參與企業優先考慮細分市場和以患者為中心的服務，以促進長期互動和治療關係，從而確保商業性擴充性和永續成長。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球非鴉片類鎮痛藥市場規模：依藥物類別分類

• NSAIDs
• COX-2抑制劑
• 抗驚厥藥物（加巴噴丁類藥物）
• SNRI
• 神經阻斷

全球非鴉片類鎮痛藥市場規模：依疼痛類型分類

• 神經病變疼痛
• 肌肉骨骼疼痛
• 術後疼痛
• 慢性疼痛

全球非鴉片類鎮痛治療市場規模：依途徑分類

• 口服
• 注射藥物
• 外用

全球非鴉片類鎮痛治療市場規模：依最終用戶分類

• 醫院
• 疼痛診所
• 零售藥房

全球非鴉片類鎮痛藥市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.（Lyrica）
• Eli Lilly（Cymbalta）
• Johnson & Johnson
• AbbVie（Cerevel）
• Averitas Pharma
• Tonix Pharmaceuticals
• Vertex Pharmaceuticals
• Trevena Inc.
• Centrexion Therapeutics
• Heron Therapeutics
• Pacira BioSciences
• Adynxx Inc.
• Epigenomics AG
• Grunenthal GmbH
• Assertio Therapeutics
• Zyla Life Sciences
• Sumitomo Pharma
• Samuels-Pennington
• Eliem Therapeutics
• Aevi Technologies

結論與建議

Global Non-Opioid Pain Treatment Market size was valued at USD 28.52 Billion in 2024 and is poised to grow from USD 30.55 Billion in 2025 to USD 52.85 Billion by 2033, growing at a CAGR of 7.12% during the forecast period (2026-2033).

The global non-opioid pain treatment market is experiencing significant growth driven by the urgent need to mitigate opioid-related harms while effectively managing chronic pain. This market encompasses a variety of pharmaceutical products, including NSAIDs, antidepressants, anticonvulsants, and topical agents, alongside device therapies such as neuromodulation and radiofrequency ablation. The importance of this market lies in its potential to provide safer and more effective pain management solutions that reduce morbidity, minimize addiction risks, and alleviate healthcare costs. As pharmaceutical companies focus on developing targeted agents and novel formulations, device manufacturers are expanding neuromodulation technology for chronic pain relief. Additionally, payers are creating reimbursement pathways that promote the integration of these treatments into clinical practice, highlighting substantial commercial and clinical opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Opioid Pain Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Opioid Pain Treatment Market Segments Analysis

Global non-opioid pain treatment market is segmented by drug class, pain type, route, end-user and region. Based on drug class, the market is segmented into NSAIDs, COX-2 Inhibitors, Anticonvulsants (Gabapentinoids), SNRIs and Nerve Blocks. Based on pain type, the market is segmented into Neuropathic Pain, Musculoskeletal Pain, Post-Surgical Pain and Chronic Pain. Based on route, the market is segmented into Oral, Injectable and Topical. Based on end-user, the market is segmented into Hospitals, Pain Clinics and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Opioid Pain Treatment Market

The increasing preference among patients for non-opioid methods of pain management is prompting healthcare providers and payer organizations to incorporate these therapies into their care protocols. This growing acceptance of alternative pain management options is likely to drive pharmaceutical and medical device manufacturers to enhance their research investments, develop diverse product portfolios, and seek regulatory approval for cutting-edge non-opioid solutions. As alternative pain management methods gain clinical traction, the resulting uplift in market volume will boost payer support and enhance visibility for manufacturers. This dynamic will accelerate commercialization efforts and foster continued growth and investment within the global non-opioid pain treatment market.

Restraints in the Global Non-Opioid Pain Treatment Market

The Global Non-Opioid Pain Treatment market faces significant challenges due to varying regulatory frameworks and intricate approval processes, which create uncertainty for developers of non-opioid therapies. These factors can lead to delays in product launches across different markets and increase the time and resources necessary for navigating approvals. This complexity can discourage smaller firms from exploring innovative solutions and complicate strategies for global commercialization. Furthermore, differences in clinical trial requirements and post-marketing surveillance expectations may result in fragmented evidence generation, inconsistent adoption by healthcare providers and payers, ultimately restricting investment, hindering product availability, and slowing market growth.

Market Trends of the Global Non-Opioid Pain Treatment Market

The Global Non-Opioid Pain Treatment market is experiencing a significant shift towards precision and personalized therapies, driven by a focus on patient stratification and biomarker-driven approaches. Stakeholders are increasingly investing in personalized formulations, targeted delivery mechanisms, and individualized care pathways, aiming to enhance the efficacy of pain management interventions and improve patient adherence. Collaborations with specialty clinics, diagnostic providers, and pharmaceutical innovators are becoming crucial for developing differentiated value propositions and achieving premium market positioning. Additionally, new market entrants are prioritizing niche segments and patient-centered services that foster long-term engagement and therapeutic relationships, ensuring commercial scalability and sustainable growth.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Non-opioid Pain Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• NSAIDs
• COX-2 Inhibitors
• Anticonvulsants (Gabapentinoids)
• SNRIs
• Nerve Blocks

Global Non-opioid Pain Treatment Market Size by Pain Type & CAGR (2026-2033)

• Market Overview
• Neuropathic Pain
• Musculoskeletal Pain
• Post-Surgical Pain
• Chronic Pain

Global Non-opioid Pain Treatment Market Size by Route & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical

Global Non-opioid Pain Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Pain Clinics
• Retail Pharmacies

Global Non-opioid Pain Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Pain Type, Route, End-User)
  • US
  • Canada
• Europe (Drug Class, Pain Type, Route, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Pain Type, Route, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Pain Type, Route, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Pain Type, Route, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (Lyrica)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (Cymbalta)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (Cerevel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Averitas Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonix Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trevena Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centrexion Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heron Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacira BioSciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adynxx Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epigenomics AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grunenthal GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Assertio Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zyla Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samuels-Pennington
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eliem Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aevi Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations